Low Dose Ara-C for Myelodysplastic Syndromes: is it Still a Current Therapy?

References

• Greenberg, P.L., Young, N.S. and Gattermann, N. (2002) "Myelodisplastic Syndromes", Hematology 2002, (Am. Soc. Hema-tol. Educ. Program), 136–161.
   Google Scholar
• Hellstrom-Lindberg, E., Willman, C., Barrett, A.J. and Saunthar-arajah, Y. (2000) "Achievement in understanding and treatment of Myelodysplastic Syndromes", Hematology 2000 (Am. Soc. Hema-tol. Educ. Program), 110–132.
   Google Scholar
• Alessandrino, E.P., Amadori, S., Cazzola, M., Locatelli, F., Mecucci, C., Morra, E., et al. (2001) "Myelodysplastic syndromes: recent advances", Haematologica, 86, 1124–1157.
   Google Scholar
• Reslcind, W.H., Steinmann, L. and Najfeld, V. (1998) "Clonal development of myeloproliferative disorders: clues to hematopoietic differentiation and multistep pathogenesis of cancer", Leukemia, 12, 128–135.
   Google Scholar
• Bennett, J.M., Catowsky, D. and Daniel, M.T. (1982) . "The French-American-British (FAB) cooperative group proposal for the classification of the myelodysplastic syndromes", Br. J. Haematol., 51, 189–199.
   Google Scholar
• Harris, N.L., Jaffe, ES., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., et al. (1999) "World Health Organization classification of neoplastic diseases of the hemato-poietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997", J. Clin. Oncol., 17, 3835–3849.
   Google Scholar
• Alessandrino, E.P., Amadori, S., Barosi, G., Cazzola, M., Grossi, A., Liberato, L.N., et al. (2002) "Evidence- and consensus-based guidelines for the therapy of primari myelodysplastic syndromes. A statement from the Italian Society of Hematology", Haematologica, 87, 1286–1306.
   Google Scholar
• Sierra, J., Perez, W.S., Rozman, C., Carreras, E., Klein, J.P., Rizzo, J.D., et al. (2002) "Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia", Blood, 100(6), 1997— 2004.
   Google Scholar
• Beran, M. (2000) "Intensive chemotherapy for patients with high-risk myelodysplastic syndrome", Int. J. Hematol., 72(2), 139–150.
   Google Scholar
• Seng, J.E. and Peterson, B.A. (1998) "Low dose chemotherapy for myelodysplastic syndromes", Leuk. Res., 22, 481–484.
   Google Scholar
• Sachs, I. (1978) " The differentiation of myeloid leukaemia cells: new possibilities for therapy". Br. J. Haematol., 40, 509–513.
   Google Scholar
• Griffin, J., Munroe, D., Major, P. and Kufe, D. (1982) "Induction of differentiation of human myeloid leukemia cells by inhibitors of DNA synthesis", Exp. Hematol., 10, 774–779.
   Google Scholar
• Cheson, B.D., Jasperse, D.M., Simon, R. and Friedman, MA. (1986) "A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes" J. Clin. Oncol., 4(12), 1857–1864.
   Google Scholar
• Koeffler, H.P. (1983) "Induction of differentiation of human acute myelogenous leukemia cells: Therapeutic implications", Blood, 62(4), 709–721.
   Google Scholar
• Baccarani, M. and Tura, S. (1979) "Differentiation of myeloid leukemic cells: new possibilities for therapy", Brit. J. Haematol., 42(3), 485–487.
   Google Scholar
• Wisch, J.S., Griffin, J.D. and Kufe, D.W. (1983) "Response of preleukemic syndromes to continous infusion of low-dose cytar-abine", New Engl. J. Med., 309, 1599.
   Google Scholar
• Au!, C. and Gatterman, N. (1992) "The role of low-dose chemotherapy in myelodisplastic syndromes", Leuk. Res., 16(3), 207 —215.
   Google Scholar
• Baccarani, M., Zaccaria, A., Bandini, G., Cavazzini, G., Fanin, R. and Tura, S. "Low dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemia", Leuk. Res., 7(4), 539–545.
   Google Scholar
• Mufti, G.J, Oscier, D.G., Hamblin, T.J., Copplestone, A. and Abidi, S.M. (1984) "Cytarabine in pre-leukemia", Lancet, 1(8387), 1187.
   Google Scholar
• Tricot, G., De Bock, R., Dekker, A.W., Boogaerts, M.A., Peeter-mans, M., Punt, K., et al. (1984) "Low dose cytosine arabinoside (Ara C) in myelodysplastic syndromes", Brit. J. Haematol., 58(2), 231–240.
   Google Scholar
• Alessandrino, E.P., Orlandi, F., Brusamolino, F., Lazzarino, M. and Bernasconi, C. (1985) "Low-dose arabinosyl cytosine in acute leukemia after a myelodysplastic syndrome and in elderly leukemia" Am. J. Hematol, 20(2), 191–193.
   Google Scholar
• Winter, N.J., Variakojis, D., Gaynor, E.R., Larson, R.A. and Miller, K.B. (1985) "Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia", Cancer, 56(3), 443–449.
   Google Scholar
• Inbal, A., Januszewicz, E., Rabinowitcz, M. and Shaklai, M. "A therapeutic trial with low-dose cytarabine in myelodysplastic syndromes and acute leukemia", Acta Haematol., 73(2), 71–74.
   Google Scholar
• Worsley, A., Mufti, G.J., Copplestone, J.A., Oscier, D.G. and Hamblin, T.J. (1986) "Very-low-dose cytarabine for myelodysplas-tic syndromes and acute myeloid leukemia in the elderly", Lancet, 1(8487), 966.
   Google Scholar
• Mineur, P., Martiat, P., Ferrant, A. and Michaux, J.L. (1989) "Low-dose cytosine arabinoside in myelodysplastic syndromes", Acta Clin. Belg., 44(1), 62–63.
   Google Scholar
• Castaigne, S., Tilly, H., Sigaux, F., Solal-Celigny, P., Bordessoule, D., Briere, J., et al. (1985) "Treatment of malignant hemopathies with aracytine in low doses. Analysis of 159 cases", Nouv. Rev. Fr. Hematol., 27(6), 377–382.
   Google Scholar
• Kufe, D.W., Spriggs, D.R. and Griffin, D.J. (1987) "Pharmacologic studies of low-dose and high-dose continuous infusion cytosine arabinoside", Semin. Oncol., 14(2 Suppl 1), 149–158.
   Google Scholar
• Powell, B.L., Capizzi, R.L., Jackson, D.V., Richards, F., Muss, H.B., Lyerly, ES., et al. (1988) "Low dose Ara-C for patients with myelodysplastic syndromes", Leukemia, 2(3), 153–156.
   Google Scholar
• Au!, C. and Schneider, W. (1989) "The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodys-plastic syndromes", Cancer, 64(9), 1812–1818.
   Google Scholar
• Hellstrom-Lindberg, E., Robert, K.H., Gahrton, G., Lindberg, G., Forsblom, A.M., Kock, Y., et al. (1992) "A predictive model for the clinical response to low dose Ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukemia", Br. J. Haematol., 81(4), 503–511.
   Google Scholar
• Miller, KB., Kim, K., Morrison, F.S., Winter, J.N., Bennett, J.M., Neiman, R.S., et al. (1992) "The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study", Ann. Hematol., 65(4),162 — 8. Erratum in: Ann. Hematol., 1993, 66(3),164.
   Google Scholar
• Bolwell, B.J., Cassileth, P.A. and Gale, R.P. (1987) "High dose cytarabine: a review", Leukemia, 2(5), 253–260.
   Google Scholar
• Ho, A.D, Martin, H., Knauf, W., Reichardt, P., Trumpel, L. and Hunstein, W. (1987) "Combination of low-dose cytarabine and 13-cis-retinoic acid in the treatment of myelodycsplastic syndromes", Leuk. Res., 11, 1041–1046.
   Google Scholar
• Clark, R.E., Ismail, SAD., Jacobs, A., Payne, H. and Smiths, S.A. (1987) "A randomized trial of 13-cis-retinoic-acid with or without cytosine arabinoside in patients with the myelodisplastic syn-dromes", Br. J. Hematol., 66, 77–83.
   Google Scholar
• Letendre, L., Noel, P., White, W.L., Tefferi, A., Litzow, M.R., Li, C.Y., et al. (1999) "Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C", Leuk. Res., 23(9), 811–815.
   Google Scholar
• Kuriya, S., Murai, K., Miyairi, Y., Utsugisawa, T., Narigasawa, Y., Ito, T., et al. (1996) "A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syn-dromes and their leukemic stage. A pilot study", Cancer, 78(3), 422–426.
   Google Scholar
• Okumura, H., Yoshida, T., Takamatsu, H., Katoh, T., Murashima, M., Watanabe, A., et al. (1997) "Treatment of acute myeloid leukemia and myelodysplastic syndrome with orally administered cytarabine ocfosfate and granulocyte colony-stimulating factor", Int. J. Hematol., 65(3), 263–268.
   Google Scholar
• Munshi, N.C. and Tricot, G.J. (1997) "Single weekly cytosine arabinoside and oral 6-thioguanine in patients with myelodysplastic syndrome and acute myeloid leukemia", Ann. Hematol., 74(3), 1 1 1 — 115.
   Google Scholar
• Venditti, A., Scimo, MT., del Poeta, G., Buccisano, F., Stasi, R., Mastino, A., et al. (1995) "Recombinant interferon alpha 2a, thymopentin and low doses of cytosine arabinoside for the treatment of myelodysplastic syndromes: a pilot study", Leuk. Lymphoma, 16(3 — 4), 335–342.
   Google Scholar
• Gerhartz, H.H., Marcus, R., Delmer, A., Zwierzina, H., Suciu, S., Dardenne, M., et al. (1994) "A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syn-dromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group", Leukemia, 8(1), 16–23.
   Google Scholar
• Fukuhara, T., Miyake, T., Maekawa, I., Kurosawa, M., Suzuki, S., Noto, S., et al. (2000) "Treatment with low-dose cytosine arabino-side followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study", Int. J. Hematol., 71(4), 366–371.
   Google Scholar
• Saito, K., Nakamura, Y., Aoyagi, M., Waga, K., Yamamoto, K., Aoyagi, A., et al. (2000) "Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation", Int. J. Hematol., 71(3), 238–244.
   Google Scholar
• Lubbert, M., Wijermans, P., Kunzrnann, R., Verhoef, G., Bosly, A., Ravoet, C., et al. (2001) "Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine", Br. J. Haema-tol., 114(2), 349 — 357.
   Google Scholar